The link between neurodegenerative diseases (NDs) and cancer has generated greater interest in biomedical research, with decades of global studies investigating neurodegenerative biomarkers in cancer to better understand possible connections. Tau, amyloid-β, α-synuclein, SOD1, TDP-43, and other proteins associated with nervous system diseases have also been identified in various types of solid and malignant tumors, suggesting a potential overlap in pathological processes. In this review, we aim to provide an overview of current evidence on the role of these proteins in cancer, specifically examining their effects on cell proliferation, apoptosis, chemoresistance, and tumor progression. Additionally, we discuss the diagnostic and therapeutic implications of this interconnection, emphasizing the importance of further research to completely comprehend the clinical implications of these proteins in tumors. Finally, we explore the challenges and opportunities in targeting these proteins for the development of new targeted anticancer therapies, providing insight into how to integrate knowledge of NDs in oncology research.
神经退行性疾病与癌症之间的联系在生物医学研究中引起了广泛关注，数十年来全球研究致力于探索癌症中的神经退行性生物标志物，以深入理解两者间可能存在的关联。Tau蛋白、β-淀粉样蛋白、α-突触核蛋白、SOD1、TDP-43等神经系统疾病相关蛋白已在多种实体瘤和恶性肿瘤中被发现，提示两类疾病可能存在病理过程的交叉。本综述旨在系统阐述这些蛋白在癌症中的作用机制，重点分析其对细胞增殖、凋亡、化疗耐药及肿瘤进展的影响。同时，我们探讨这种关联性对疾病诊断与治疗策略的启示，强调需通过深入研究以全面理解这些蛋白在肿瘤中的临床意义。最后，我们针对以这些蛋白为靶点开发新型抗癌疗法所面临的挑战与机遇展开讨论，为神经退行性疾病研究成果在肿瘤学研究中的整合应用提供新视角。
Insights into Dysregulated Neurological Biomarkers in Cancer
肿瘤(癌症)患者之家